“Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes” published in Diabetes Care.

Despite being an important inflammatory biomarker implicated in endothelial and podocyte dysfunction, suPAR’s predictive qualities for complications in type 1 diabetes have yet to be determined. This study by Viktor Rotbain Curovic et al., including 667 participants, investigated the value of suPAR for the prognostic value for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.

A higher level of suPAR showed to be a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. suPAR also significantly contributes to discrimination for the end points.

Read the full article here